Bafna Pharmaceuticals

Bafna Pharmaceuticals

188.65
-3.79
(-1.97%)
hide
Key Fundamentals
Add Ratio
Market Cap
455.20 Cr
EPS
-15.52
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
192.44
52 Week Low
69.00
PB Ratio
8.74
Debt to Equity
0.70
Forecast For
Actual

Company News

View All News
Caret
positive
Bafna Pharmaceuticals Limited reported its unaudited financial results for the quarter and half year ended September 30, 2025. The company achieved revenue from operations of INR 3,546.82 lakhs for Q2 2025, compared to INR 3,462.40 lakhs in Q2 2024. Net profit for the quarter stood at INR 312.49 lakhs versus INR 338.89 lakhs in the previous year quarter. For the half year period, revenue reached INR 7,009.22 lakhs with net profit of INR 651.38 lakhs. The company's total assets increased to INR 16,068.27 lakhs as of September 30, 2025, up from INR 13,215.84 lakhs in the previous year. Earnings per share for Q2 2025 was INR 1.32. The auditors noted outstanding foreign currency receivables of INR 213 lakhs beyond RBI stipulated time periods and an income tax refund adjustment of INR 45.17 lakhs under legal proceedings.
neutral
Bafna Pharmaceuticals Appoints New Independent Director, Re-appoints Two OthersSep 19, 2025
Bafna Pharmaceuticals Limited shareholders approved the appointment of Mr. Navin Kumar as Non-Executive Independent Director for a one-year term effective June 23, 2025, at their 30th Annual General Meeting held on September 19, 2025. The meeting also approved the re-appointment of Mr. Palamadai Krishnan Sundaresan and Mrs. Ravichandran Chitra as Non-Executive Independent Directors for second terms of five years each, effective September 19, 2025 and November 12, 2025 respectively. Mr. Kumar is a Chartered Accountant with over 13 years of experience in corporate finance, taxation, and auditing. Mr. Sundaresan is a Cost & Management Accountant and Company Secretary with over 40 years of multi-industry experience. Mrs. Chitra holds a Bachelor's degree in Commerce and brings over three decades of experience in Human Resource Management. All three directors are confirmed as not being debarred from holding office by any regulatory authority.
positive
Bafna Pharmaceuticals Re-appoints Two Independent Directors and CEO for Five-Year TermsAug 12, 2025
Bafna Pharmaceuticals Limited's Board of Directors approved the re-appointment of Mrs. Ravichandran Chitra and Mr. Palamadai Krishnan Sundaresan as Non-Executive Independent Directors for second terms of five years each, effective November 12, 2025 and September 19, 2025 respectively, subject to shareholder approval. The Board also re-appointed Mr. Bafna Mahaveer Chand as Chief Executive Officer for a further five-year term effective September 10, 2025. Mrs. Chitra brings over three decades of experience in Human Resource Management and related fields, while Mr. Sundaresan is a qualified CMA and CS with over 40 years of multi-industry experience. Mr. Chand, a Chemistry graduate with over four decades in the pharmaceutical industry, has led the company to establish a DSIR-approved R&D centre, secure UK-MHRA accreditation, and win multiple national and international awards for quality and excellence.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,732.10
#1 4,11,749.90
39.63
#1 54,729.00
9.71
#1 10,980
2.89
66.26
6,520.00
1,73,603.20
69.64
9,712.00
18.67
2,191
35.10
50.59
3,824.60
1,29,482.50
60.46
11,539.40
6.99
1,911
30.46
70.50
1,519.30
1,22,366.70
22.59
28,409.50
7.12
5,291
3.71
44.46
1,229.60
1,01,113.50
#1 17.88
33,741.20
16.73
5,725
-0.38
47.35
951.40
94,475.30
19.03
23,511.00
18.55
4,615
34.60
39.39
2,270.00
91,653.00
52.89
12,744.20
#1 20.90
2,007
-21.05
32.59
2,033.90
90,250.10
21.39
22,909.50
13.74
3,306
#1 72.75
62.84
5,767.50
68,110.20
29.54
13,458.30
3.70
2,216
21.39
70.49
1,183.60
67,849.20
20.35
32,345.60
9.43
3,484
3.81
67.18
Growth Rate
Revenue Growth
-2.95 %
Net Income Growth
-90.21 %
Cash Flow Change
-1,816.76 %
ROE
-96.42 %
ROCE
-90.07 %
EBITDA Margin (Avg.)
-112.00 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Jun 2019
Sept 2019
Revenue
12
9
7
12
Expenses
14
9
10
12
EBITDA
-2
0
-3
0
Operating Profit %
-15 %
2 %
-42 %
-3 %
Depreciation
1
1
1
1
Interest
1
1
0
0
Profit Before Tax
-4
-1
-4
-1
Tax
0
0
-2
0
Net Profit
-4
-1
-2
-1
EPS in ₹
0.00
-0.80
-0.90
-0.25

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
Total Assets
200
193
178
138
120
71
Fixed Assets
55
53
49
45
37
35
Current Assets
127
123
77
49
49
36
Capital Work in Progress
0
0
0
0
0
0
Investments
0
0
17
0
0
0
Other Assets
145
140
113
94
82
36
Total Liabilities
200
193
178
138
120
71
Current Liabilities
111
95
82
60
71
17
Non Current Liabilities
16
40
55
41
30
3
Total Equity
73
58
42
37
19
51
Reserve & Surplus
53
39
20
14
-5
-7
Share Capital
19
19
19
24
24
2

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
Net Cash Flow
0
-0
-0
0
-0
6
Investing Activities
60
-0
-5
38
15
33
Operating Activities
11
1
-1
-7
-2
-34
Financing Activities
-71
-1
6
-31
-14
7

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
91.74 %
90.39 %
90.40 %
90.42 %
90.42 %
90.12 %
90.00 %
90.02 %
90.00 %
90.00 %
88.74 %
88.43 %
88.30 %
88.30 %
88.30 %
88.30 %
75.00 %
75.00 %
75.00 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
8.53 %
9.34 %
9.34 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
6.31 %
6.23 %
6.26 %
6.10 %
5.24 %
5.50 %
5.62 %
5.61 %
5.64 %
5.64 %
6.87 %
7.66 %
7.48 %
7.37 %
7.69 %
7.66 %
11.06 %
11.62 %
12.03 %
Others
1.95 %
3.37 %
3.34 %
3.49 %
4.33 %
4.38 %
4.38 %
4.37 %
4.37 %
4.36 %
4.39 %
3.91 %
4.23 %
4.34 %
4.01 %
4.04 %
5.40 %
4.04 %
3.63 %
No of Share Holders
8,603
8,330
8,068
7,910
7,326
7,223
7,275
7,199
7,120
6,992
7,354
7,367
7,539
7,391
7,295
7,214
7,142
7,283
7,572

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
25 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
25 Sept 2024 82.30 80.11
11 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Nov 2024 80.13 81.90
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 77.43 78.02
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 May 2025 76.88 73.00
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Aug 2025 83.14 91.46
19 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
19 Sept 2025 91.46 130.85
11 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Nov 2025 170.25 192.35

Announcements

Unaudited Financial Results For The Quarter And Half Year Ended September 30 20251 day ago
Board Meeting Outcome for Outcome For The Board Meeting Held On 11/11/20251 day ago
Board Meeting Intimation for Meeting Scheduled On November 11 20256 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 10, 2025
Closure of Trading WindowSep 26, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 19, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateSep 19, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 28, 2025
Notice Of 30Th Annual General Meeting Of The Company For The F.Y 2024-2025Aug 26, 2025
Reg. 34 (1) Annual Report.Aug 26, 2025
Book Closure For 30Th Annual General Meeting (AGM)Aug 21, 2025
Shareholder Meeting - 30Th AGM On September 19 2025Aug 21, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateAug 12, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 12, 2025
Unaudited Financial Results For The Quarter Ended June 30 2025Aug 12, 2025
Board Meeting Outcome for Outcome For The Board Meeting Held On 12/08/2025Aug 12, 2025
Board Meeting Intimation for Meeting Scheduled On August 12 2025Aug 07, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 05, 2025
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015Jun 30, 2025
Closure of Trading WindowJun 26, 2025
Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Re-Constitution Of CommitteesJun 24, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateJun 24, 2025
Announcement under Regulation 30 (LODR)-RetirementJun 24, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 23, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateJun 23, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
Audited Financial Results For The Quarter & Year Ended March 31 2025May 26, 2025
Board Meeting Outcome for Outcome For The Board Meeting Held On 26/05/2025May 26, 2025
Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Re-Constitution Of Nomination & Remuneration Committee.May 20, 2025
Board Meeting Intimation for Board Meeting Scheduled On May 26 2025May 19, 2025
Announcement Under Reg 30 Of SEBI (LODR) Regulations 2015 - AwardApr 29, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateApr 01, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorApr 01, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Apr 01, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Apr 01, 2025
Disclosure Under Regulation 7(2) Of SEBI (PIT) Regulations 2015Mar 31, 2025
Notice of Offer for Sale of Shares by Promoter & Flooor PriceMar 26, 2025
Closure of Trading WindowMar 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 11, 2025
Integrated Filing (Financial)Feb 06, 2025
Unaudited Financial Results For The Quarter And Nine Months Ended 31/12/2024Feb 06, 2025
Board Meeting Outcome for Board Meeting Held On 06/02/2025Feb 06, 2025
Board Meeting Intimation for Board Meeting Scheduled On February 06 2025Jan 28, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 09, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 16, 2024
Unaudited Financial Results For The Quarter Ended 30.09.2024Nov 11, 2024

Technical Indicators

RSI(14)
Neutral
79.71
ATR(14)
Less Volatile
5.42
STOCH(9,6)
Overbought
100.00
STOCH RSI(14)
Overbought
100.00
MACD(12,26)
Bullish
4.70
ADX(14)
Strong Trend
30.59
UO(9)
Bearish
90.94
ROC(12)
Uptrend And Accelerating
39.27
WillR(14)
Overbought
0.00